1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Bavarian Nordic Seeks Partner After RSV Jab Generates Glowing Phase II Data

Danish Biotech CEO Says Commercializing MVA-BN RSV Is Key Objective Now

 
• By Sten Stovall

Solid Phase II data for Bavarian Nordic’s investigational vaccine MVA-BN RSV showed falls in both symptoms and viral load of respiratory syncytial virus in the challenge trial’s adult participants, boosting prospects for a Phase III trial - and for finding a commercial partner.  

Candidate Vaccine MVA-BN RSV Contains Five Different Antigens of RSV virus • Source: Alamy

Bavarian Nordic A/S’s respiratory syncytial virus vaccine program has been markedly de-risked after the administration of candidate MVA-BN RSV in a Phase II adult challenge trial led to a big reduction in viral load compared with placebo, paving the way for talks with regulators for the design of a Phase III study and with prospective partners to commercialize the product.

The Phase II trial enrolled 61 healthy adult volunteers aged 18 to 50 randomized to receive either a single vaccination of MVA-BN RSV or placebo and then challenged intranasally with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

More from R&D

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 
• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.